After combining the top 25 KEGG results with PPI data, it was observed that AKT1 was present in 23 pathways, with the exceptions of “MicroRNAs in cancer” and “Bladder cancer.” EGFR was identified in 22 pathways, excluding “Cellular senescence,” “Acute myeloid leukemia,” and “Small cell lung cancer.” BCL2 appeared in 11 pathways, including “Pathways in Cancer” and “Prostate Cancer,” among others. Here, BCL2 is linked to prostate carcinoma.